Cassandra | Technologies

Cassandra is a powerful AI system that harnesses real world data on drugs and data obtained from the FDA and EMA post-marketing requirements (PMRs) databases. This information is used by Cassandra to predict the probability that the US Food & Drug Administration (FDA) and European Medicines Agency (EMA) will require post-marketing studies. This could be critical to the overall success of a new product.

Cassandra AI

Cassandra is trained using machine learning and data obtained from FDA and EMA post-marketing requirements and commitments databases.

Key benefits

Mitigate:

Being able to anticipate the demands of regulatory authorities allows us to define a mitigation strategy early in the drug development cycle, and this could be critical to the overall success of a new product.
Plan:

Ask Cassandra about any drug(s) currently in development, and its AI brain will provide an instant and reliable verdict on the probability of a PMR and the background context, providing sponsors with an invaluable planning tool.
Success:

Commercialisation teams can work with confidence on their post-marketing strategy based on genuine insight into future threats and opportunities. They can also gather enough additional long-term safety data on patients treated during the early phases of the development cycle to convince the authorities that a post-authorisation safety study is not needed.

Request a demo

Applying AI to manage the risks and costs of postmarketing requirements

Our award-winning Cassandra AI system harnesses real world data on drugs and data obtained from the US FDA and EMA postmarketing requirements databases to accurately forecast whether postmarketing studies will be necessary.

Read the whitepaper

Cassandra AI

Key benefits

Mitigate:

Plan:

Success:

Applying AI to manage the risks and costs of postmarketing requirements

Factsheet: Cassandra

Citeline Awards 2024 winner

Silver Stevie Award Winner at the 21th Annual International Business Awards

In this section

Connect with us